Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4509-4516

  Wong, Richard J ^a   Chan, Mei Ki ^a   Yu, Zhenkun ^a   Ghossein, Ronald A ^a   Ngai, Ivan ^a   Adusumilli, Prasad S ^a   Stiles, Brendon M ^a   Shah, Jatin P ^a   Singh, Bhuvanesh ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEMOGLOBIN; HERPESVIRUS VECTOR; INTERLEUKIN 12; MATRIGEL; MONOKINE; ONCOLYTIC VIRUS; VIRUS ONCOLYSATE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOGLOBIN DETERMINATION; HERPES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMOKINES, CXC; COCULTURE TECHNIQUES; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRIDAE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LAMININ; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; TIME FACTORS; TRANSFECTION; TRANSGENES;

EID: 3042770658     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0081     Document Type: Article

References (35)

1. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
2. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-85.
3. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13:1325-34.
4. Walker JR, McGeagh KG, Sundaresan P, et al. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999;10: 2237-43.
5. Wong RJ, Kim SH, Joe JK, et al. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001;193:12-21.
6. Bennett JJ, Kooby DA, Delman K, et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 2000;78:166-74.
7. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther 2000;11:1683-93.
8. Ebright MI, Zager JS, Malhotra S, et al. Replication-competent herpes virus NV 1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg 2002;124:123-9.
9. Wong RJ, Joe JK, Kim SH, et al. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 2002;13: 1213-23.
10. Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999;10:1599-606.
11. Wong RJ, Chan M, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing IL-12. Clin Cancer Res 2004;10:251-9.
12. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther 2000;7:867-74.
13. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
14. Fong Y, Kemeny N, Jarnagin W, et al. Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Proc Am Soc Clin Oncol 2002;21:8a.
15. Wong RJ, Patel SG, Kim SH, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001;12:253-65.
16. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-14.
17. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (aotus trivirgatus). J Infect Dis 1990;162:313-21.
18. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998;5:121-30.
19. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000;97:2208-13.
20. Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 2003;52:133-44.
21. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 178:1223-30.
22. Bramson JL, Hitt M, Addison CL, et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996;7:1995-2002.
23. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;7:3877-82.
24. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (Bethesda) 1995;87: 581-6.
25. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002;5:668-75.
26. Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 2001;8:282-90.
27. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264-9.
28. Fu KK, Rayner PA, Lam KN. Modification of the effects of continuous low-dose radiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys 1984;10:1473-8.
29. O'Malley BW, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-4.
30. Khurana D, Martin EA, Kasperbauer JL, et al. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck 2001;23:899-906.
31. Strasly M, Cavallo F, Geuna M, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001;166:3890-9.
32. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol 1992;148:3433-40.
33. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Investig 2000;105:841-6.
34. Yao L, Sgadari C, Furuke K, et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93: 1612-21.
35. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999;10: 2741-55.